The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
Recruitment status was Not yet recruiting
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria or Angioedema: A Randomised Controlled Study|
- The frequency and severity of CIU and/or angioedema (as determined via a five point rating scale)
- The relative use of antihistamines (ie how many, how often)
|Study Start Date:||September 2005|
The role of dietary pseudoallergens as a trigger for CIU and/or Angioedema is a controversial subject. 'Dietary Pseudoallergy' refers to the mimicking of IgE symptoms (such as rash, itch and swelling) by components of food in the absence of a true IgE mediated response (as diagnosed by RAST and skin prick testing).
The pseudoallergen-free diet excludes a range of naturally occuring chemicals (including salicylates, amines and brewers yeast) in addition to a range of artificial preservatives and additives (for example sulphites and glutamates). The control diet is based on the general dietary guidelines for the management of diabetes (including the principles of healthy eating, low glycemic index choices and a reduced saturated fat intake).
Subjects recruited into the study will have a 3 month history of CIU and/or Angioedema and will be randomly assigned to either the active or control arm of the study in a single blinded fashion. All subjects will be advised to cease antihistamine medication and will receive one-on-one dietary counselling by a Dietitian. The diet to which each subject has been assigned (ie either active or placebo) is to be followed for a 4 week duration. The frequency and severity of CIU and/or Angioedema as well as adherence to the diet are to be measured on both a daily and weekly basis by the subject via the completion of a clinical score card. The results of the score cards will be collated to determine the relative effects of each diet on these conditions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00163839
|Contact: Kate L Connell, Masters||0061 3 9276 firstname.lastname@example.org|
|Contact: Jo Douglass, FRACP MD||0061 3 9276 email@example.com|
|Alfred Hospital||Not yet recruiting|
|Melbourne, Victoria, Australia, 3004|
|Contact: Kate L Connell, Masters 0061 3 9276 3063 firstname.lastname@example.org|
|Contact: Jo Douglass, FRACP MD 0061 3 9276 3836 email@example.com|
|Principal Investigator: Kate L Connell, Masters|
|Sub-Investigator: Jo Douglass, FRACP MD|
|Principal Investigator:||Kate Connell, Masters||Alfred Hospital, Melbourne, Australia|